المملكة المتحدة - الإنجليزية - MHRA (Medicines & Healthcare Products Regulatory Agency)

advanz pharma - oxprenolol hydrochloride - modified-release tablet - 160mg

سنغافورة - الإنجليزية - HSA (Health Sciences Authority)

biotronik asia pacific pte. ltd. - cardiovascular - rivacor belongs to a family of implantable cardioverter-defibrillators (icds). the primary objective of the therapy is to prevent sudden cardiac death. furthermore, the device is capable of treating bradycardia arrhythmias and cardiac resynchronization therapy with multisite ventricular pacing. the implantation of an icd is a symptomatic therapy with the following objectives: termination of spontaneous ventricular fibrillation (vf) through shock delivery; termination of spontaneous ventricular tachycardia (vt) through antitachycardia pacing (atp); in case of ineffective atp or hemodynamically not tolerated vts, with shock delivery; cardiac resynchronization through multisite ventricular pacing (triple-chamber devices); compensation of bradycardia through ventricular (single-chamber devices) or av sequential pacing (dx, dual- and triple- chamber devices). vr-t dx and hf-t/hf-t qp devices types with dx functionality are only indicated for patients not requiring atrial pacing.

المملكة المتحدة - الإنجليزية - MHRA (Medicines & Healthcare Products Regulatory Agency)

amdipharm plc - oxprenolol hydrochloride - oral tablet - 40mg

المملكة المتحدة - الإنجليزية - MHRA (Medicines & Healthcare Products Regulatory Agency)

amdipharm plc - oxprenolol hydrochloride - oral tablet - 20mg

المملكة المتحدة - الإنجليزية - MHRA (Medicines & Healthcare Products Regulatory Agency)

amdipharm plc - oxprenolol hydrochloride - oral tablet - 80mg

المملكة المتحدة - الإنجليزية - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - oxprenolol hydrochloride - oral tablet - 80mg

المملكة المتحدة - الإنجليزية - MHRA (Medicines & Healthcare Products Regulatory Agency)

stephar (u.k.) ltd - oxprenolol hydrochloride - oral tablet - 80mg

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

nova pharmaceuticals australasia pty ltd - clotrimazole, quantity: 1 % w/w; hydrocortisone acetate, quantity: 1 % w/w - cream - excipient ingredients: cetostearyl alcohol; ceteareth-20; propylene glycol; light liquid paraffin; purified water - broad spectrum anti-fungal and anti-inflammatory cream for dermatophyte and yeast infections of the skin when inflammation is prominent. this includes conditions such as tinea (athlete's foot, jock itch, ring worm), fungal skin rash, thrush infections of the skin, fungally infected nappy rash and eczema/dermatitis.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

nova pharmaceuticals australasia pty ltd - clotrimazole, quantity: 1 % w/w; hydrocortisone acetate, quantity: 1 % w/w - cream - excipient ingredients: ceteareth-20; purified water; propylene glycol; light liquid paraffin; cetostearyl alcohol - broad spectrum anti-fungal and anti-inflammatory cream for dermatophyte and yeast infections of the skin when inflammation is prominent. this includes conditions such as tinea (athlete's foot, jock itch, ring worm), thrush infections of the skin, and fungally infected eczema/dermatitis.